“We do not lack cures. We lack the infrastructure to pay for and deliver them,” writes William Padula.
Vetenskapsnyheter
Unmet vascular needs can lead to limb loss among unhoused patients. An unusual Massachusetts General Hospital program meets patients where they are.
You're reading the web edition of STAT's ADA in 30 Seconds, from the American Diabetes Association's annual conference.
Boehringer Ingelheim’s obesity drug showed promise in cutting liver fat, but it was less impressive at overall weight loss, new data shows.
You're reading the web edition of STAT's ADA in 30 Seconds, from the American Diabetes Association's annual conference in New Orleans.
Eli Lilly presented new safety and tolerability data on retatrutide at the annual meeting of the American Diabetes Association on Saturday.
Detailed data from a midstage study offered further evidence that the obesity drug Pfizer acquired from the biotech Metsera could be dosed monthly.
There may be nearly 2 million Amish Americans by 2075. That has large public health implications.
“Ebola is an unforgiving enemy,” writes Tom Frieden, who led the U.S. CDC response to the 2014-2016 Ebola outbreak.
The Ebola outbreak in Central Africa could grow to 20,000 cases or more, depending on how quickly infected people are isolated to slow the spread, according to a new U.S. analysis.
You're reading the web edition of STAT's ADA in 30 Seconds, from the American Diabetes Association's annual conference in New Orleans.
Thousands of HHS staff who shape policy have had their employment status changed to a designation that makes it easier for them to be fired
An NIH advisor told researchers gathered at the American Diabetes Association conference that MAHA goals match the agency's priorities.
When I deployed to Sierra Leone during the 2014-2016 West Africa Ebola epidemic, I understood the risks. Every physician, nurse, epidemiologist, laboratorian, and aid worker who enters an Ebola outbreak…
RevMed's cancer drug feels out of reach for some, SCOTUS preserves key generic drug pathway, and more biotech news
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
The limitations of private health insurance, the quiet collapse of America's research ethics watchdog and other Morning Rounds news
Drugmakers and patient groups asked the FDA to pause former commissioner Marty Markary's National Priority Voucher drug review program
“I believe deeply in universal health care. But universal care must also mean universal safety and accountability, not merely universal access.”
OHRP has experienced an unprecedented exodus of ethics expertise, raising concerns about its ability to effectively protect volunteers.
Americans who have high-risk exposures to Ebola in the current outbreak in Central Africa will have access to an experimental antibody treatment.
The White House has used the program to reward companies that help its political goals.
Why did a presentation on Revolution Medicines' pancreatic cancer drug get a standing ovation? Why did biotech stocks perform so badly this week? Find out on "The Readout LOUD."
Otsuka’s Voyxact slowed the loss of kidney function after one year in patients with a chronic autoimmune kidney disease, but the benefit was less than expected.
The Supreme Court unanimously ruled that Hikma Pharmaceutical did not infringe patents held by Amarin in a decision with implications for lawsuits over so-called skinny labels.